What does Kringle Pharma, Inc. do?
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated…
What is Kringle Pharma, Inc.'s P/E and P/B ratio?
Kringle Pharma, Inc. has a P/E ratio of -5.8 and a P/B ratio of 3.86.
What is Kringle Pharma, Inc.'s debt-to-equity ratio?
Kringle Pharma, Inc. has a debt-to-equity ratio of 0.00.
How much does Kringle Pharma, Inc. owe compared with what it owns?
Kringle Pharma, Inc. owes ¥0.37 for every ¥1 it owns (balance sheet Jun 2026), which is low.
What is Kringle Pharma, Inc.'s Positivity rank?
Kringle Pharma, Inc. is ranked #8,977 of 10,750 companies globally and #3,499 of 3,683 in Japan on PositoAI, with a Positivity Score of 18,043.
Does Kringle Pharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for Kringle Pharma, Inc..
Where can I read the latest news about Kringle Pharma, Inc.?
Recent headlines about Kringle Pharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Kringle Pharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Kringle Pharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.